INTRODUCTION

43
Staphylococcus aureus is a major cause of both community-and hospital-acquired infections and 44 represents a significant burden on the healthcare system. In addition, S. aureus is also involved in 45 infections of medical implants and host tissue due to its ability to form biofilms, which play an 46 important role in the persistence of chronic infections (1, 2). A biofilm is defined as a sessile 47 microbial community in which microorganisms live attached to a surface in a highly hydrated 48 extracellular matrix (3), which in case of S. aureus is composed of host factors, secreted and lysis-49 derived proteins, polysaccharides, and eDNA (4). Biofilm cell population shows structural and 50 functional heterogeneity. Depletion of nutrients causes microbes to enter a metabolically quiescent 51 state. In addition, biofilms accommodate a high level of persister cells, an isogenic sub-population 52 of bacteria tolerant to antibiotics that is characterized by a slow-or non-growing state (5, 6). The 53 presence of the extracellular matrix and the heterogeneity of the cellular metabolic status make 54 biofilm-embedded bacteria up to 1000 times more resistant to most antimicrobial agents than their 55 planktonic counterparts (7, 8) . The challenge of biofilm treatment spur scientists to investigate 56 alternative strategies for its eradication. In this context, bacteriophage therapy, based on the 57 administration of viruses selectively infecting target bacteria (9, 10), has re-emerged as potential 58 therapeutic option in cases where antibiotics alone are not able to eradicate the biofilm (11, 12) .
59
Recently, different studies investigated the effect of the combined phage/antibiotic treatment 60 against biofilm-embedded cells. Ryan et al showed that a synergistic effect of cefotaxime was 61 observed when used in combination with the T4 phage against Escherichia coli biofilm (13). Two 62 independent studies also demonstrated that pre-treating Pseudomonas aeruginosa (14) and S. 
68
In this study, we aimed to evaluate the susceptibility of S. aureus biofilm to Sb-1 bacteriophage 69 administered with fosfomycin, rifampin, vancomycin daptomycin and ciprofloxacin, either 70 simultaneously or in staggered treatment. In addition, we examined the ability of Sb-1 to degrade 71 extracellular matrix and to target persister and metabolically less active cells of S. aureus biofilm. 
RESULTS
81
Sb-1 phage lyses Staphylococcus aureus planktonic cells, but it does not eradicate the biofilm. 82 We evaluated the lytic spectrum of Sb-1 on a collection of S. aureus clinical isolates from implant-83 associated infections (29 MSSA and 28 MRSA strains) . The MRSA ATCC 43300 was also 84 included. 27 MRSA strains -including ATCC 43300 -and 20 MSSA strains were susceptible to 85 Sb-1, as indicated by the appearance of plaques of lysis. The parameters of the viral cycle of the 86 phage during the infection of ATCC 43300, which was used for anti-biofilm experiments, are 87 reported in Table 1 . In order to evaluate Sb-1 potential anti-biofilm activity, 24 hour-biofilm-88 coated glass beads were exposed to Sb-1 titers ranging from 10 2 to 10 7 PFU/mL for 24 hours, and 89 then transferred into fresh media, where the heat flow produced by the replication of cells still 90 adhering on the bead was followed by microcalorimetry. The treatment with Sb-1 determined a 91 strong reduction in the heat flow as compared to the growth control already at the low titers tested
92
( Figure 1 ). However, only the highest titer (10 7 PFU/mL) was able to inhibit the heat production 93 more than 90% compared to the growth control, defined as the MBBC according to (16).
94
Moreover, when sonication fluids obtained from the beads were plated, bacterial growth was 95 observed, proving that, despite the strong reduction in viable cells, 10 7 PFU/mL of Sb-1 could not 96 completely eradicate the biofilm.
97
Simultaneous treatment with Sb-1 and rifampin/daptomycin results in eradication of S.
98
aureus biofilm.
99
We evaluated whether simultaneous treatment with Sb-1 and conventional antibiotics may produce 100 a synergistic effect resulting in the complete eradication of the biofilm. We first tested the 101 susceptibility of both planktonic and biofilm-embedded S. aureus ATCC 43300 cells to five observed for all the antibiotics tested ( Figure 4 and Table 3 ), although the effect was minimal in 108 the case of fosfomycin ( Figure 4A ). Notably, a synergistic effect occurred when using 10 5 PFU/mL Staggered phage and antibiotic treatment is the most effective for biofilm eradication.
114
We then tested the effect of uncoupling the phage/antibiotic treatment and replacing it with a 115 staggered treatment. We treated the biofilm-coated beads for 24 hours with sub-eradicating amount Sb-1 degrades the extracellular polysaccharide matrix.
133
The effect of Sb-1 on biofilm matrix of MRSA ATCC43300 was assessed by confocal microscopy.
134
A 24 hours old biofilm was stained with two dyes, specific for the poly-N-acetylglucosamine 135 residues of the extracellular polysaccharides and the cellular DNA, respectively. As we expected, Sb-1 targets also persister cells.
142
We tested the activity of Sb-1 on free floating i) cells scraped from the biofilm; ii) ciprofloxacin- PFU/mL in any of the conditions tested. By contrast, the 10 7 PFU/mL titer determined a reduction 147 of the CFU/mL (≈ 2-5 log10 CFU), demonstrating that the phage displayed lytic activity regardless were inoculated into BHI broth and incubated in the presence of glass beads at 37°C for 24 hours.
239
The minimum heat inhibitory concentration (MHIC) for planktonic bacteria was defined as the was evaluated by CFU counting of the sonicated beads. biofilm (24h-old) was exposed for 24 hours to different Sb-1 titers (ranging from 10 4 to 10 MRSA biofilm (24h-old) was exposed for 24 hours to different Sb-1 titers (ranging from 10 4 to 10 6 PFU/mL) and then stained with green fluorescent labeled WGA488 (488/500-600 nm) for exopolysaccharides and SYTO™85 (561/600-700 nm) for bacterial cells. An untreated control was also added. Scale bar: 25 μm. Figure 8. CLSM images of MRSA ATCC43300 biofilm untreated and treated with Sb-1. MRSA biofilm (24h-old) was exposed for 24 hours to different Sb-1 titers (ranging from 10 4 to 10 6 PFU/mL). The viability of the cells was evaluated stained with green fluorescent labeled Syto 9 (488/500-540 nm) for alive bacteria and with red fluorescent Propidium iodide (PI) (561/600-650 nm) for dead bacteria. An untreated control (0) was also added.
Scale bar: 25 μm. and CCCP-induced persisters (Persisterscccp) were exposed to either 10 4 and 10 7 PFU/mL Sb-1 in PBS+1% BHI for 3 hours at 37°C. Untreated controls were also added. After phage treatment, cells were plated to enumerate CFUs. Data are means with standard deviation, and the dotted line represents the detection threshold. A set of samples treated as above-mentioned and washed to remove un-adsorbed phages, was also inoculated in fresh BHI for 24 hours and then the turbidity was visually evaluated (on the bottom panel).
